Eli Lilly and Company (NYSE:LLY) is highlighted as a promising stock by Jim Cramer, who discusses the potential of the company’s weight loss drug, particularly its upcoming pill version. Despite a recent stock surge, caution is advised due to the unpredictability of the pharmaceutical industry. Eli Lilly is known for developing pharmaceuticals in various areas such as diabetes, obesity, oncology, immunology, and neuroscience. While Eli Lilly shows promise as an investment, there are AI stocks with potentially greater upside and lower risk. For more information on undervalued AI stocks, a free report is available.

Read more at Yahoo Finance: Jim Cramer on Eli Lilly: “We’re Not a Seller”